SAb Biotherapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 86

Employees

  • Stock Symbol
  • SABS

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.81
  • (As of Friday Closing)

SAb Biotherapeutics General Information

Description

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Contact Information

Website
www.sab.bio
Formerly Known As
Hematech, Big Cypress Acquisition
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 777 West 41st Street
  • Suite 401
  • Miami Beach, FL 33140
  • United States
+1 (305)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 777 West 41st Street
  • Suite 401
  • Miami Beach, FL 33140
  • United States
+1 (305)

SAb Biotherapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SAb Biotherapeutics Stock Performance

As of 20-Nov-2026, SAb Biotherapeutics’s stock price is $2.81. Its current market cap is $253M with 90.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.81 $2.91 $2.44 - $5.15 $253M 90.1M 627K -$1.35

SAb Biotherapeutics Financials Summary

As of 30-Sep-2026, SAb Biotherapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 190,927 73,356 9,137 65,653
Revenue 0 0 0 0
EBITDA (82,223) 15,164 (30,280) (38,718)
Net Income (80,520) 13,274 (34,105) (42,194)
Total Assets 235,644 172,810 44,195 83,941
Total Debt 4,918 5,951 4,669 5,907
Public Fundamental Data provided by Morningstar, Inc. disclaimer

SAb Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SAb Biotherapeutics‘s full profile, request access.

Request a free trial

SAb Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore SAb Biotherapeutics‘s full profile, request access.

Request a free trial

SAb Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency
Drug Discovery
Miami Beach, FL
86 As of 2025

Wilmington, DE
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SAb Biotherapeutics Competitors (55)

One of SAb Biotherapeutics’s 55 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Kite Pharma Formerly VC-backed Santa Monica, CA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 55 competitors. Get the full list »

SAb Biotherapeutics Patents

SAb Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022104127-A1 Ungulate-derived polyclonal immunoglobulin specific for egfr and uses thereof Inactive 13-Nov-2020
WO-2022104152-A1 Ungulate-derived polyclonal immunoglobulin specific for pd-l1 and uses thereof Inactive 13-Nov-2020
US-11975066-B2 Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof Active 31-Aug-2020
US-20220062405-A1 Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof Active 31-Aug-2020
US-20240374704-A1 Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof Pending 31-Aug-2020 A61K39/12
To view SAb Biotherapeutics’s complete patent history, request access »

SAb Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SAb Biotherapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore SAb Biotherapeutics‘s full profile, request access.

Request a free trial

SAb Biotherapeutics Acquisitions (1)

SAb Biotherapeutics’s most recent deal was a Merger/Acquisition with Big Cypress Acquisition for . The deal was made on 25-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Big Cypress Acquisition 25-Oct-2021 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view SAb Biotherapeutics’s complete acquisitions history, request access »

SAb Biotherapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view SAb Biotherapeutics’s complete esg history, request access »

SAb Biotherapeutics FAQs

  • When was SAb Biotherapeutics founded?

    SAb Biotherapeutics was founded in 2014.

  • Where is SAb Biotherapeutics headquartered?

    SAb Biotherapeutics is headquartered in Miami Beach, FL.

  • What is the size of SAb Biotherapeutics?

    SAb Biotherapeutics has 86 total employees.

  • What industry is SAb Biotherapeutics in?

    SAb Biotherapeutics’s primary industry is Drug Discovery.

  • Is SAb Biotherapeutics a private or public company?

    SAb Biotherapeutics is a Public company.

  • What is SAb Biotherapeutics’s stock symbol?

    The ticker symbol for SAb Biotherapeutics is SABS.

  • What is the current stock price of SAb Biotherapeutics?

    As of 20-Nov-2026 the stock price of SAb Biotherapeutics is $2.81.

  • What is the current market cap of SAb Biotherapeutics?

    The current market capitalization of SAb Biotherapeutics is $253M.

  • Who are SAb Biotherapeutics’s competitors?

    Ayala Pharmaceuticals, Inovio Pharmaceuticals, Marengo Therapeutics, Kite Pharma, and Intellia Therapeutics are some of the 55 competitors of SAb Biotherapeutics.

  • What is SAb Biotherapeutics’s annual earnings per share (EPS)?

    SAb Biotherapeutics’s EPS for 12 months was -$1.35.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process